Shu Wang, Yuguang Guan and Tianfu Li* Pages 1 - 11 ( 11 )
Epilepsy is one of the most common serious neurological disorders, affecting over 70 million people world-wide. For treatment of epilepsy, antiepileptic drugs (AEDs) and surgeries are widely used. However, drug resistance and adverse effects indicate the need to develop targeted AEDs based on further exploration of the epileptogenic mechanism. Currently, many efforts have been made elucidate to the neuro inflammation theory in epileptogenesis, which may show potentialin treatment of epilepsy. In this respect, an important target protein, high mobility group box 1 (HMGB1), has received increased attention and has been developed rapidly. HMGB1 is expressed in various eukaryotic cells and localized in the cell nucleus. When HMGB1is released by injuries or diseases, it participates in inflammation. Recent studies suggest that HMGB1 via Toll-like receptor (TLR) pathways can trigger inflammatory responses and play an important role in epilepsy. In addition, studies of HMGB1 have shown its potential in treatment of epilepsy.Herein, the authors analyzedthe experimental and clinical evidence of the HMGB1-TLR pathway in epilepsy to summarize the theory of epileptogenesis and provideinsights into antiepileptic therapy in this novel field.
Neuroinflammation, HMGB1, TLR, HMGB1-TLR pathway, Epilepsy, antiepileptic drugs
Department of Neurosurgery, SanBo Brain Hospital, Capital Medical University, Beijing 100093, Department of Neurosurgery, SanBo Brain Hospital, Capital Medical University, Beijing 100093, Department of Neurology, SanBo Brain Hospital, Capital Medical University, Beijing 100093